Darbepoetin Alfa BS Injection 30mcg Syringe [JCR] (ダルベポエチンアルファBS注30μgシリンジ「JCR」)

Страна: Японія

мова: англійська

Джерело: すりの適正使用協議会 RAD-AR Council, Japan

Активний інгредієнт:

Darbepoetin alfa(genetical recombination)[darbepoetin alfa biosimilar1]

Доступна з:

Kissei Pharmaceutical Co., Ltd.

ІПН (Міжнародна Ім'я):

Darbepoetin alfa(genetical recombination)[darbepoetin alfa biosimilar1]

Фармацевтична форма:

injection

інформаційний буклет

Drug Information Sheet("Kusuri-no-Shiori")
Injection
Revised: 07/2023
The information on this sheet is based on approvals granted by the
Japanese regulatory authority. Approval
details may vary by country. Medicines have adverse reactions (risks)
as well as efficacies (benefits). It is
important to minimize adverse reactions and maximize efficacy. To
obtain a better therapeutic response,
patients should understand their medication and cooperate with the
treatment.
BRAND NAME:
DARBEPOETIN ALFA BS INJECTION 30MCG SYRINGE
[JCR]
ACTIVE INGREDIENT:
Darbepoetin alfa(genetical recombination)[darbepoetin
alfa biosimilar1]
DOSAGE FORM:
injection
IMPRINT OR PRINT ON WRAPPING:
EFFECTS OF THIS MEDICINE
This medicine acts on cells that grow into red blood cells (RBCs) to
increase the number of
RBCs and consequently improves anemia attributable to renal diseases.
It is usually used in the treatment of renal anemia.
THE FOLLOWING PATIENTS MAY NEED TO BE CAREFUL WHEN USING THIS
MEDICINE.BE SURE TO TELL YOUR DOCTOR
AND PHARMACIST.
・If you have previously experienced any allergic reactions (itch,
rash, etc.) to any medicines
or foods.
If you have a history of myocardial infarction, pulmonary infarction
or cerebral infarction.
If you have: hypertension.
・If you are pregnant or breastfeeding.
・If you are taking any other medicinal products. (Some medicines may
interact to enhance or
diminish medicinal effects. Beware of over-the-counter medicines and
dietary supplements
as well as other prescription medicines.)
DOSING SCHEDULE (HOW TO TAKE THIS MEDICINE)
・
Your dosing schedule prescribed by your doctor is((         

to be written by a healthcare
professional
))
・For hemodialysis patients: In general, for adults and children,
inject intravenously once per
week or once every two weeks.
For patients with chronic kidney disease not on dialysis and
peritoneal dialysis patients: In
general, for adults and children, inject subcutaneously or
intravenously once every two or
four weeks.
In any case,